Dediabetes Logo
Questions
Published answers connected to evidence
Clinical Reference
Detailed intervention and outcome dossiers
Latest Research
Newest studies
About
How deDiabetes works
Settings
Login / Sign-up
Research Summary
Analyzed using Evidence Intelligence™

Liraglutide improves beta-cell function in type 2 diabetes

Powered by the Dediabetes Evidence Intelligence™ framework

Last updated September 12, 2026

Key finding

Liraglutide increased the disposition index [B total × ISI composite, by 40% (n=24, p<0.001)].

The study investigated the effects of liraglutide on beta-cell function in individuals with well-controlled type 2 diabetes, finding a significant improvement in the disposition index.

Quick read

Study at a glance

The essential study design details in one scan.

EvidenceScore™

Moderate

Study type

RCTs

Follow-up

Medium-Term (3–12 mo)

Risk of bias

Some Concerns

Save research, organize studies, and quickly find important evidence again.

Plain-language summary

What this paper says

A plain-language read of the study’s main message and where it applies.

Study focus

The study investigated the effects of liraglutide on beta-cell function in individuals with well-controlled type 2 diabetes, finding a significant improvement in the disposition index.

Clinical relevance

Improving beta-cell function is crucial for managing type 2 diabetes effectively. Liraglutide's ability to enhance insulin secretion and reduce blood sugar levels could lead to better long-term outcomes for patients, potentially reducing the risk of diabetes-related complications.

Keep in mind

Sample size for some outcomes was small, limiting generalizability. Effectiveness of liraglutide compared to metformin and placebo remains unclear. No long-term follow-up data were provided.

Published in

Journal Reference

Publication details and source links for this paper.

Christian A, Preman K, Anders J, et al. The insulinotropic drug liraglutide improves beta-cell function in well-controlled type 2 diabetes. Diabetology & Metabolic Syndrome. 2019;11:42. doi:10.1186/s13098-019-0438-6

View DOIView on PubMedView on PMC

Main Effects

Liraglutide increased the disposition index by 40% (n=24, p<0.001).

Post-prandial insulin and glucose were reduced by metformin in combination with liraglutide.

Liraglutide may reduce post-prandial glucose without increasing insulin concentration.

Evidence network

How this study fits

Understand where this research contributes within the broader evidence network.

Evidence Context

This study contributes evidence to Liraglutide and Disposition Index, Glucagon, Insulin clearance, and 2 more.

This study contributes evidence to

Intervention

Liraglutide

Outcome

Disposition Index

Evidence topic

Glycemic Control

Primary intervention

Liraglutide

Primary outcomes

  • Disposition Index
  • Glucagon
  • Insulin clearance

Evidence topics

Glycemic ControlPost-Meal and OGTT GlucoseGLP-1 Receptor AgonistsLiraglutide

Primary intervention

Liraglutide

Primary outcomes

Disposition IndexGlucagonInsulin clearance

Evidence relationships

Intervention and outcome relationships this study adds to the evidence network.

5
Evidence pairs
5
Relationships
4
Evidence topics
contributes_evidence

Editorial context

Why this study matters

See why this paper is useful beyond its individual results.

Evidence network role

This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.

Moderate contributionModerate confidenceNetwork score: 68

4

Related topics

5

Evidence pairs

786

Related studies

High relevance in at least one topic

Why it is useful

  • Contributes to 5 evidence relationships
  • Includes primary outcome data
  • Linked to 4 direct semantic evidence topics

Topic contributions

Evidence topic

Contributes evidence

Evidence topic

Contributes evidence

Evidence topic

Contributes evidence

Evidence topic

Contributes evidence

Add related evidence to your Evidence Tracker

Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.

Primary evidence

Evidence relationship

GLP-1 Receptor Agonists and Postprandial and OGTT Glucose

Related evidence

Evidence topic

Glycemic Control

Save evidence

Evidence topic

Post-Meal and OGTT Glucose

Save evidence

Core evidence

Study findings

The primary outcomes reported in this study.

Disposition Index

Liraglutide → Disposition Index

Liraglutide → Disposition Index

Evidence Intelligence™
EvidenceScore™
Emerging
Score 59 · Based on 1 study
ImpactScore™
100
Very Positive
ConsistencyScore™
unclear
Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence Tracker

Glucagon

Liraglutide → Glucagon

Liraglutide → Glucagon

Evidence Intelligence™
EvidenceScore™
Emerging
Score 59 · Based on 1 study
ImpactScore™
50
Neutral
ConsistencyScore™
unclear
Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence Tracker

Insulin clearance

Liraglutide → Insulin clearance

Liraglutide → Insulin clearance

Evidence Intelligence™
EvidenceScore™
Emerging
Score 59 · Based on 1 study
ImpactScore™
50
Neutral
ConsistencyScore™
unclear
Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence Tracker

Post-prandial insulin response after mixed-meal test

Liraglutide → Post-prandial insulin response after mixed-meal test

Liraglutide → Post-prandial insulin response after mixed-meal test

Evidence Intelligence™
EvidenceScore™
Emerging
Score 59 · Based on 1 study
ImpactScore™
50
Neutral
ConsistencyScore™
unclear
Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence Tracker

Postprandial blood glucose

Liraglutide → Postprandial blood glucose

Liraglutide → Postprandial blood glucose

Evidence Intelligence™
EvidenceScore™
Emerging
Score 59 · Based on 1 study
ImpactScore™
50
Neutral
ConsistencyScore™
unclear
Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence Tracker

Evidence Library

Build your evidence library

Save research, organize studies, and quickly find important evidence again.

evidence suggest

Evidence Suggest

  • Liraglutide improved the disposition index by 40% (p<0.001).
  • Post-prandial glucose reduction was noted with liraglutide.
  • Glucagon levels remained unchanged during liraglutide therapy.
who this applies

Who this applies to

  • Adults with well-controlled type 2 diabetes.
  • Participants who are currently on metformin therapy.
keep in mind

Keep in Mind

  • Results may not be applicable to individuals with poorly controlled diabetes.
  • Further studies are needed to confirm long-term effects.
  • The study did not explore the effects of liraglutide in diverse populations.
between the lines

Between the Lines

  • Sample size for some outcomes was small, limiting generalizability.
  • Effectiveness of liraglutide compared to metformin and placebo remains unclear.
  • No long-term follow-up data were provided.

Evidence Library

Build your evidence library

Save research, organize studies, and quickly find important evidence again.

Connected Evidence

Explore related studies, evidence collections, and research questions.

Relationships organized using the Dediabetes Evidence Intelligence™ framework.

Powered by the Dediabetes Evidence Intelligence™ framework

This study contributes to evidence on GLP-1 Receptor Agonists and Disposition Index, GLP-1 Receptor Agonists and Glucagon.

Related evidence relationships

Explore in Evidence Explorer

This study contributes to the evidence on the following intervention-outcome relationships.

Questions answered by this study

Generated from the study's connected evidence using Evidence Intelligence™.

Do GLP-1 Receptor Agonists improve postprandial and ogtt glucose?

Strong Evidence

GLP-1 Receptor Agonists may improve postprandial and ogtt glucose.

ConsistencyScore™: Results are consistent across studies.

Ranked evidence signals

  1. 1

    Postprandial blood glucose

    EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study

Why this answer: This answer is based on 10 supporting studies with consistent results and a positive effect signal.

10 supporting studies
View Full Evidence

Does Liraglutide improve disposition index?

Emerging Evidence

Liraglutide appears to improve disposition index.

ConsistencyScore™: Consistency cannot yet be determined from the available evidence.

Ranked evidence signals

  1. 1

    Disposition Index

    EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study

Why this answer: This answer is based on a single supporting study.

Limitations

  • Only one supporting study is available.
1 supporting study
View Full Evidence

Does Liraglutide improve glucagon?

Emerging Evidence

Current evidence does not show a clear benefit of Liraglutide for glucagon.

ConsistencyScore™: Consistency cannot yet be determined from the available evidence.

Ranked evidence signals

  1. 1

    Glucagon

    EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study

Why this answer: This answer is based on a single supporting study.

Limitations

  • Only one supporting study is available.
1 supporting study
View Full Evidence

Does Liraglutide improve insulin clearance?

Emerging Evidence

Current evidence does not show a clear benefit of Liraglutide for insulin clearance.

ConsistencyScore™: Consistency cannot yet be determined from the available evidence.

Ranked evidence signals

  1. 1

    Insulin clearance

    EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study

Why this answer: This answer is based on a single supporting study.

Limitations

  • Only one supporting study is available.
1 supporting study
View Full Evidence
Learn how Evidence Intelligence™ works

Next steps

Continue your research

Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.

Evidence topics

Follow the topics this study contributes to.

Glycemic Control Evidence HubPost-Meal and OGTT Glucose Evidence HubGLP-1 Receptor Agonists Evidence HubLiraglutide Evidence Hub

Explore in Evidence Explorer

Open broader Evidence Explorer views for this relationship.

All studies on Liraglutide and Disposition IndexAll studies on Liraglutide and Postprandial blood glucoseAll studies on Liraglutide and GlucagonAll studies on Liraglutide and Insulin clearance

Related research

Read related research summaries.

Liraglutide is well tolerated in diabetes patients undergoing hemodialysis.Liraglutide may reduce stroke recurrence in type 2 diabetes patientsGLP-1RA improves metabolic outcomes in MASLDLiraglutide 3 mg pathway improves weight loss.Liraglutide improves glycaemic control in adults with T2D

No ads. No tracking.

Focused on evidence, not advertising.

Secure & private

Your data is always protected.

Always up to date

New studies added every day.